ABOUT H4 ORPHAN PHARMA
At H4 Orphan Pharma, a French pharmaceutical company created in 2016, we are revolutionizing the therapeutic approach to fibrotic diseases.
Our pipeline currently includes two drug candidates with worldwide commercial potential, both targeting orphan diseases:
idiopathic pulmonary fibrosis - dry eye in Sjögren syndrome
